Inflammatory bowel disease [IBD], including ulcerative colitis and Crohn's disease, is a chronic and unpredictable condition characterised by alternating periods of remission interspersed with relapses. In recent years, accumulating support for an immunomodulating effect of vitamin D on both the innate and the adaptive immune systems has been presented. Through the vitamin D receptor, the active form of vitamin D, 1,25[OH] 2 D, induces antimicrobial peptide secretion, decreases dendritic cell activity, and promotes Th2 and regulatory T cell development and activity. In addition, vitamin D promotes an increased ratio of anti-inflammatory cytokines to pro-inflammatory cytokines. Studies in IBD point to a role for vitamin D in ameliorating disease outcome. Suboptimal circulating levels of 25-hydroxyvitamin D are common in IBD and appear to be associated with an increased risk of flares, IBD-related hospitalisations and surgeries, an inadequate response to tumour necrosis factor [TNF] inhibitors, a deterioration in quality of life, and low bone mineral density. With only few available randomised double-blind, placebo-controlled studies investigating therapeutic effects of vitamin D related to IBD, further research is necessary to determine the true therapeutic potential of vitamin D, as well as to define its optimal range in serum to achieve and maintain quiescence of disease. This review aims to summarise the latest knowledge on the extraskeletal effects of vitamin D in IBD, and outlines the potential deleterious consequences of vitamin D deficiency in this patient cohort.
Introduction
Ulcerative colitis and Crohn's disease are the two major entities under the umbrella term of inflammatory bowel disease [IBD] 1, 2 which has emerged as a public health challenge worldwide. 3 IBD is a multifactorial disease with a complicated pathogenesis still incompletely understood. However, four main factors are known to interact and contribute to the chronic intestinal inflammation: intestinal antigens, genetic susceptibility, an overly reactive immune response, and various environmental triggers. 4, 5 It is well-known that patients with IBD have an increased risk of osteopenia and osteoporosis, and several factors including malabsorption of calcium and/or vitamin D caused by flaring disease or previous surgery, diminished food intake, and medications which inhibit bone formation or increase bone turnover interfering with calcium absorption and normal mineralisation of bone. [6] [7] [8] However, when focusing on vitamin D in calcium homeostasis and bone health, 9 both disease and non-disease-related elements are proposed to contribute to low levels of vitamin D in IBD. These include inadequate sunlight exposure, an impaired enzymatic activation, lower bioavailability, increased catabolism or excretion, insufficient physical activity, and smoking.
influence the gut microbiome. [14] [15] [16] [17] Recent data indicate that it also improves iron recycling through downregulatory effects on hepcidin, with resulting higher haemoglobin levels in patients with IBD. 18, 19 As epidemiological studies have documented that vitamin D deficiency is frequent in IBD, 20, 21 it is presumed that its supplementation may counteract a number of inflammatory-related complications. 12, 13, 15, 22 Consistent with this hypothesis, a number of clinical studies have linked vitamin D levels with meaningful clinical outcomes in patients with IBD in recent years. [23] [24] [25] Independently of other variables, lower vitamin D levels are associated with a greater risk of clinical relapse, for example. [25] [26] [27] More robust causative evidence has emerged from interventional studies of vitamin D supplementation. [28] [29] [30] Cumulatively, this body of work supports a potential role for vitamin D as a therapeutic agent in patients with IBD.
The aim of the present review is to summarise updated data on the potential role of vitamin D in the pathophysiology of IBD as identified in Box with Search Strategy, with an emphasis on its impact on disease outcomes, and to provide practical guidance for its clinical use.
Physiological Role of Vitamin D

Vitamin D and its effects on skeletal health
In humans the fat-soluble vitamin D is present in two main forms, vitamin D2 [ergocalciferol, from plant sources] and vitamin D3 [cholecalciferol, from animal sources]. Both are absorbed as a dietary vitamin in the small intestine or endogenously synthesised in the skin in response to ultraviolet light exposure [ Figure 1 ], 8, 11, 31 which is the main source, facilitated when the sun's ultraviolet B [UVB] rays convert 7-dehydrocholesterol to pre-vitamin D3.
After its endogenous synthesis or intestinal absorption, vitamin D is transported to the liver where it is metabolised by the enzyme 25- 37 a process which may also be affected by an impact of inflammation on PTH levels. 38 The active metabolite of vitamin D executes its potential beneficial actions on cells through the vitamin D receptor [VDR] , which functions as a transcription factor to control gene expression and is present in several organs, including skeletal muscle, immune cells, and the intestine. 12, 15 Consequently, vitamin D is involved in a wide range of physiological processes. 16 The 
The innate immune system
The epithelial lining of the gut acts as an important physical barrier for the host against luminal content, including food antigens and the microbiota. 41 Thus, tight junctions and adherent junctions between the epithelial cells are essential to maintain a continuous barrier, 42 as leakage through altered junctions will increase intestinal permeability, which may give rise to inflammation. 43 Studies have shown that a pore-forming transmembrane protein, claudin-2, increases intestinal permeability by inducing cation-selective channels in the tight junctions. 44 Patients with IBD have an increased expression of channel-forming claudin-2 as compared with heathy controls. 45 The expression of claudin-2 is stimulated by interferon [IFN]-γ, a pro-inflammatory cytokine, whereas the protein tyrosine phosphatase N2 [PTPN2] inhibits its expression. In this context, the 1, 25 [OH] 2 D-VDR complex can induce transcription of the gene coding for PTPN2, resulting in an inhibition of claudin-2, protecting the intestinal barrier 12 and maintaining the differentiated adhesive phenotype of intestinal epithelial cells. 46 When activated by pathogens, the intestinal epithelium and macrophages produce cathelicidin, which is an antimicrobial peptide, 47, 48 as well as defensins which maintain and protect the intestinal barrier integrity. 12, 49 31 which adds further evidence of the role of vitamin D in enhancing the innate immune defenses. 11 Further, an intervention study in patients with ulcerative colitis demonstrated that high doses of vitamin D3 led to increased levels of cathelicidin in peripheral blood cells. 51 Mutations of the gene NOD2 is associated with a higher risk of developing Crohn's disease, 52, 53 as well as a more complicated disease course, 54 as the anti-inflammatory feature of the NOD2 weakens in these carriers. 55 In this context, vitamin D has been found to be a direct inducer of the expression of NOD2 and its downstream pathway, and a synergistic effect on antimicrobial peptide expression by Table 1 . Effects of vitamin D on the innate and adaptive immune system [animal studies separate from human studies].
Innate immune system
Adaptive immune system
In vitro or animal studies
Low levels of VDR are associated with chronic inflammation and downregulated expression of ATG16L1 vitamin D pre-treatment and successive muramyl dipeptide [MDP] activation has been reported.
56
ATG16L1 is a gene essential in the process of autophagy and thereby in maintaining intestinal homeostasis, especially in Crohn's disease. 57 ATG16L1 is expressed in intestinal epithelium, dendritic cells, and T and B cells, thus affecting not only the innate but also the adaptive immune system, 5, 57, 58 and recently VDR was shown to transcriptionally regulate this gene. 59 Thus, in experimental models of colitis, low levels of VDR are associated with chronic inflammation and a downregulated expression of ATG16L1. 57, 60 Finally, it has lately been shown that activated group3 innate lymphoid cells [ILC3s], which are tissue-resident lymphocytes functionally resembling TH17/22 cells in the adaptive system, are rendered responsive to vitamin D by upregulating VDR, which causes downregulation of the IL-23R pathway and simultaneous shifts of the ILC3 cytokine production to proinflammatory cytokines, e.g. IL-6 and IL-8. Hence, targeting VDR could have a therapeutic potential in IBD that might directly affect ILC3 functions crucial in orchestrating innate immune responses. 61 Taken together, these emerging data establish a modulatory role for vitamin D to restore the mutualistic interplay between the microbiota and the epithelium in IBD.
62,63
The adaptive immune system
Dendritic cells link the innate immune system to the adaptive immune system by presenting antigens to T cells and inducing an adaptive response through T cell-secreted cytokines. 64 Dendritic cells have a reduced response to lipopolysaccharide when stimulated with 25 [OH]D3, 65 which results in a decreased activation of T cells, 66 thus preventing over-activation of the inflammatory response. Dendritic cells also express VDR, and when the receptor is bound by 1,25[OH] 2 D, dendritic cells inhibit the inflammatory response by promoting IL-10 production and inhibiting IL-12 production. This change in cytokine production favours the Th2 lymphocyte development over Th1 lymphocyte development, leading to an antiinflammatory state. 31 Other mechanisms through which vitamin D may exert its modulating role include an increased production of the anti-inflammatory cytokine IL-10 in CD4 + T cells from Crohn's disease when stimulated with 1,25[OH] 2 D3, 67, 68 as well as apoptosis of activated Th1 cells, reducing pro-inflammatory mediators [TNF-α, IFN-γ, ICAM-1]. [69] [70] [71] [72] Very lately it has been revealed in a prospective cohort of patients with ulcerative colitis in remission, that high serum vitamin D correlates with greater serum anti-inflammatory to pro-inflammatory cytokine ratios, and that such anti-inflammatory cytokine phenotypes are associated with increased presence of histological mucosal healing and decreased risk of clinical relapse. 73 Vitamin D also promotes the transcription factors c-maf and GATA-3, leading to the maturation of Th2 cells. 70 In addition to T cell regulation, the production of anti-inflammatory cytokines, including IL-4, IL-10, and TGF-β, is increased by vitamin D. 70 Cumulatively, these effects suppress initiation and persistence of adaptive responses to exogenous triggers, a critical feature of chronic inflammation in IBD. 70 
Thresholds for Vitamin D Supplementation
The discovery of non-renal production of 1,25 [ 31, 77 and no consensus exists. 12, 13, 17 It has been suggested that immunomodulatory or other non-skeletal effects require concentrations higher than 75 nmol/L. 22, 78 Above this level, PTH reaches a nadir, and renal 1α-hydroxylase is suppressed, 79 which may encourage production of 1,25[OH]D via non-renal pathways. 80 Nonetheless, clinical studies in patients with IBD [ Table 2 ] often use the RDA as the definition of 'inadequacy', which in real-world situations could lead to an overestimation of people being vitamin D deficient. 74 This highlights the limitation of using cut-off points determined for bone health from older populations to determine the need for supplementation in patients with IBD. 76 Before patients take vitamin D supplements they should, however, be calcium replete, as 1,25[OH] 2 D mobilises calcium stores from bone. [81] [82] [83] [84] Although most research has emphasised the possible benefits of vitamin D, it should be noted that supplemental intake of greater than 4000 IU per day increases the risk of hypervitaminosis D, which is associated with an increased risk of fractures and falls, 85 as well as renal calculi. 86 Recent epidemiological data have also pointed to an increased risk of pancreatic cancer, prostate cancer, and all-cause mortality correlated with high 25[OH]D serum levels. 75 The known and purported benefits of sufficient vitamin D have caused some people to believe that taking doses higher than the RDA has even more value. Lately, investigators used a US Health and Nutrition Survey Database to identify about 5000 participants for each 2-year cycle of dietary assessment [from 1999 to 2014], for a total of 39 243 participants [mean age 47] . 76 In the 2013-2014 Converted from nmol/L to ng/mL by dividing by a factor 2.5.
survey, the prevalence of daily supplemental intake ≥1000 IU vitamin D was 18.2%, and the prevalence of intake ≥4000 was 3.2%. It was observed that the intake increased significantly from the 1999-2000 survey [0.3%] to the 2013-2014 survey. 76 However, as hypervitaminosis D, as mentioned, is linked with serious side effects, caution is advised and clinicians should be asking patients specifically about their supplemental vitamin D use.
Relationship of Vitamin D Levels to Natural History of IBD
Given the noted impact of malabsorption and inflammation on serum vitamin D levels, 24, 87, 88 it is no surprise that vitamin D deficiency seems to occur more frequently in IBD than in the general population. 13, 87, 89, 90 Prevalence rates of vitamin D deficiency in IBD range from 16% to 95%, and it seems to occur more commonly in Crohn's disease than in ulcerative colitis. Nevertheless, observational studies focusing on vitamin D and its effects on the clinical course and outcome in IBD are conflicting [ Table 2 ]. Thus in one study, 60 patients with IBD were included, of whom 95% had vitamin D deficiency defined as <29 ng/mL. 92 The patients were divided into active or quiescent disease, but no association between vitamin D and disease activity was revealed. Another study had similar findings in a cohort of 119 patients with Crohn's disease. 93 Additionally, this latter trial assessed the systemic inflammatory burden by measuring C-reactive protein [CRP] , and no correlation with serum level of vitamin D was found [ Table 2 ].
In contrast, a cross-sectional study 94 24 In this study, vitamin D deficiency was prevalent in IBD and appeared to be linked to an increased disease activity, as the risk of relapse was almost doubled in patients with Crohn's disease and vitamin D concentrations below 50 nmol/L, and it was deducted that correction of vitamin D deficiency would be beneficial for controlling the disease. 24 Another cross-sectional study has supported this association by noting higher health-related quality of life in a cohort of 220 patients with IBD during periods of raised vitamin D levels 96 [ Table 2 ]. Further, a study exclusively performed on 50 patients with ulcerative colitis supported the association between lower levels of serum 25 [OH]D and disease activity. 97 Here patients receiving glucocorticoids were excluded because of the interaction of glucocorticoids with vitamin D metabolism. Patients were divided into two groups, and a significantly higher concentration of serum 25 [OH]D was found in the group with mild disease activity as compared with the moderate disease activity group. 97 The limitation of many studies has been their retrospective or cross-sectional correlation of vitamin D with disease activity indices, which does not answer the causation question. To address this, a recent prospective study of 70 patients with ulcerative colitis in clinical remission, followed for 12 months, reported that a serum level of 25 [OH]D of 87.5 nmol/L or less during periods of clinical remission was associated with an increased risk clinical relapse over the subsequent 12 months. 98 Similarly, a prospective 5-year longitudinal study involving 965 IBD patients [62% with Crohn's disease and 38% with ulcerative colitis] 25 found an association between vitamin D and health-related outcome. Low 25[OH]D levels [i.e. <75 nmol/l] were observed in 30% of patients at study entry, and were highest among young males. 25 During the 5-year followup, patients with low 25[OH]D levels required significantly more glucocorticoids, initiation of biologic treatment, narcotics for pain control, computed tomography scans, emergency department visits, hospitalisations, and surgery, than did those with normal 25[OH] D levels. 25 To control for the effect of disease severity on 25 [OH]D levels, the investigators conducted a subgroup analysis of patients in clinical remission at study entry. In this group more patients with low versus normal 25 [OH]D levels required glucocorticoids [51% and 37%, respectively] and IBD-related surgery [34% and 22%, respectively]. 25 Moreover, patients with low vitamin D levels who were administered vitamin D supplementation progressively reduced their health care use during the 5-year follow-up, whereas those with low 25[OH]D levels who did not receive supplementation converseely increased their health care use. This extensive study with a comprehensive IBD cohort was able to associate low 25 [OH] D to a multiplicity of outcomes, and thus it adds substantial information to the increasing amount of evidence connecting 25 [OH]D levels with outcomes in IBD. 27 Another comprehensive prospective study of 3217 patients with IBD showed that low 25[OH]D is associated with higher risk of IBD-related surgery and hospitalisations. 
Response to biologics
Although most of the patients included in the previous studies received medication, not many of the studies explored the relationship between 25 [OH]D levels and the probability of remission while on a certain medication. Nevertheless, in a subgroup of 37 patients with Crohn's disease, an early increase of serum 25 [OH]D was observed in those responding to tumour necrosis factor [TNF] inhibitors, 95 and recently a similar observation was noticed in ulcerative colitis as well. 100 Moreover, in a single-centre cohort study of 101 patients with IBD, pre-treatment levels of 25[OH]D influenced durability of TNF inhibitors. 101 This trial supported the relevance of both correcting and maintaining adequate vitamin D levels in IBD above 75 nmol/l to reduce the risk of flares and to optimise response to targeted medical regimens. 26, 101 Finally, a recent retrospective study on 384 patients with IBD treated with TNF inhibitors concluded that IBD patients with normal 25[OH]D levels at the initiation of treatment with TNF inhibitors had a 2.64 increased chance of reaching remission within 3 months as compared with those patients with low vitamin D concentrations. 100 
Vitamin D as a Therapy for IBD
Experimental studies in mice have previously shown vitamin D to reduce the severity of colitis. 102, 103 However, in humans, vitamin D deficiency or impaired signalling might worsen colitis through multiple effects, including alterations of the gut microbiome, 59, 60, 83, [104] [105] [106] and vitamin D supplementation has been reported to increase both bacterial richness and bacterial diversity. 107 Nevertheless, only a few randomised controlled trials have examined the effects of vitamin D supplementation on outcome of IBD. In a small placebo-controlled, randomised trial of Crohn's disease in remission, 94 patients were randomly divided into two groups: one group receiving 1200 IU vitamin D3 daily, and the other receiving placebo. The trial concluded that dietary supplementation with vitamin D3 daily for 12 months modestly increased the participants ' 25 [OH]D levels and reduced the proportion of patients with clinical relapse from 29% to 13%. 28 Although this difference was not statistically significant [p = 0.06], the study did support the rationale for further studies.
In 29 Although it was revealed that patients in Arm B had significantly lower levels of circulating IL-6 and CRP [p <0.05], the daily doses of vitamin supplementation in both arms were inadequate to maintain the predefined serum 25 [OH]D concentrations of 80 nmol/L or above at the follow-up visits, though doses were safe and well tolerated. The findings of an association between intake of higher doses of vitamin D and reduced inflammatory surrogate markers may, however, indicate that vitamin D repletion and supplementation regimens should be based on body weight. 29, 108 Supplementing all patients with the same amount of vitamin D might, however, result in patients with a low basal level not reaching the therapeutic threshold. Nevertheless, this was not relevant in an intervention study on 18 patients with Crohn's disease, 30 which applied a design focusing on achieving 25 [OH]D levels of 100 nmol/L, instead of receiving a fixed daily dose of vitamin D. After 6 months, the authors reported a highly significant reduction in CDAI scores. Unfortunately this study had certain limitations, including a very small study cohort and the lack of a control group. 30 A randomised controlled trial included 90 patients with quiescent ulcerative colitis. 51 The study design was different from other studies as it only intervened once by administering 300 000 IU vitamin D3 intramuscularly or 1 mL saline [placebo] . Systemic inflammation, measured as level of serum CRP, was assessed 3 months after intervention, presenting a decrease in the group receiving vitamin D3. 51 Another randomised, double-blind placebo-controlled trial in 34 patients with quiescent Crohn's disease compared the effect of high-dose vitamin D3 supplementation of 10 000 IU daily [n = 18 patients] versus 1000 IU daily [n = 16]. The cohort was supplemented for a full year, after which the study reported similar rates of clinical relapse in both treatment groups, although high-dose supplementation significantly improved 25 [OH]D levels. 109 To address some of the problems with under-dosing of vitamin D in intervention trials, a recent prospective pilot study of 10 patients with active IBD and a serum 25 [OH]D level below 75 nmol/L had 'treat-to-target' dosing of vitamin D to get 25[OH] levels up to 125 nmol/L. Subjects were dose-adjusted 4-weekly to aim for a target level of 100-126 nmol/L. Per-oral doses used in the protocol were 5000-10 000 U/day. Over the 12 weeks of the study, the mean increase was 20 ng/mL, with most patients needing at least one 4-week period of 10 000 U/day. Target or near-target was achieved in all participants over 12 weeks and, though a signal for hypercalciuria was noted in one patient, the regimen was well tolerated and symptom-based activity scores improved. 110 The available studies have confounders or limitations. These may include variations in: cut-off levels of serum 25 [OH]D values used to define 'deficiency'; study populations and designs; inclusion and exclusion criteria; activity scores applied; treatment doses; and outcomes. Direct comparisons between studies are further complicated by the lack of a standardisation between various assays used to measure 25 [OH]D levels. 111 However, results seem to support the concept of vitamin D having anti-inflammatory effects in IBD [ Figure 2 ].
24,26
Conclusions and Recommendations
Laboratory, epidemiological, and clinical studies support the concept that vitamin D may in part determine the development of, and course of, IBD beyond its classical key role in bone health and calcium homeostasis.
It is as yet unclear whether vitamin D deficiency is a causative factor for IBD or a risk factor, but vitamin D deficiency seems to be prevalent in IBD and to be inversely linked to disease activity, more frequent relapses, higher postoperative recurrence, poorer quality of life, and failure of response to biologics, as compared with normal or high levels of 25 [OH]D in IBD. However, there is a need for the definition of the optimal therapeutic level of 25 [OH]D in IBD and to clarify how vitamin D modifies levels of inflammation; its exact effect on disease severity, and if vitamin D deficiency is associated with any specific clinical phenotypes. Thus, it is likely that higher concentrations of serum 25 [OH]D may be required in active IBD to achieve the immunological effects noted in vitro. Finally, a number of challenges occur when designing future trials to examine the importance of vitamin D supplementation, as placebo arms may be exposed to either the therapeutic intervention from vitamin D-enriched food or to sun exposure, blurring whether the intervention actually causes the expected effect. 13, 112 Furthermore, leaving vitamin D deficiency untreated might even be unethical.
Nevertheless, this manuscript highlights a broad array of data supporting the importance of ensuring at least adequate [>75nmol/L] serum vitamin D levels in patients with IBD. This may improve clinical outcomes, such as relapse rate and mucosal inflammation, in addition to its benefits on bone health. Animal models, as well as epidemiological studies and intervention studies, have all provided a scientific rationale for this approach. The primary area lacking data is appropriately sized, randomised controlled trials of vitamin D supplementation, adjusted to obtain such adequate levels in an intervention cohort. Due to a lack of an industry sponsor to fund such complex studies, these are unlikely to emerge from investigator-initiated studies. In this setting, and in light of the accumulated literature reviewed here, we recommend that physicians and other health care professionals check the 25[OH]D serum levels of their patients with IBD regularly. To avoid vitamin D insufficiency it is of importance to consider vitamin D supplementation which, unlike other current IBD therapies, is relatively affordable and accessible. This may increase the probability of clinical remission and response to conventional therapeutic strategies, and in this way may lead to better patient outcomes as well as reduced health care expenses. 
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Take-home Points
